Abacus Parenteral Drugs Limited

abacusparenteral.com

Trading in pharmaceutical products is one of core industry in Uganda‘s economy. As the manufacturers of pharmaceutical products are very few to cater the market demand, majority of demand was met through importation. This business is growing at a rapid pace with the growth of population and export potential to neighbour countries like Kenya, Rwanda, Burundi, Congo, Sudan etc. Nonetheless the Government support by removal of taxes on imports of Pharmaceutical products, to sustain its policies of providing proper medication to people, also provided a vital support for its accelerating growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

news image

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

news image

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More

FIXX PHARMACEUTICALS WANTS TO DOMINATE HEMOPHILIA MARKET WITH GENE EDITING

Prnewswire | August 28, 2020

news image

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop ...

Read More

Pharma Tech

MARK CUBAN COST PLUS DRUG COMPANY AND HEALTHDYNE ANNOUNCE PHARMACY PARTNERSHIP

PRNewswire | June 08, 2023

news image

Ongoing changes in the healthcare industry have fueled innovators to reinvent the future, forge new paths, make smart decisions, and find aligned partners to disrupt the traditional pharmacy space. HealthDyne and Cost Plus Drugs have partnered to deliver pharmacy solutions for a new era in medication therapy distribution. HealthDyne, the national provider of digital pharmacy services, was selected by Cost Plus Drugs to expand its pharmacy operations. "Healthcare companies h...

Read More
news image

Business Insights

NOVABAY PHARMACEUTICALS COLLABORATES WITH HARROW HEALTH’S IMPRIMISRX TO PROMOTE PRESCRIPTION AVENOVA

NovaBay Pharmaceuticals | July 20, 2021

NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...

Read More
news image

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More
news image

FIXX PHARMACEUTICALS WANTS TO DOMINATE HEMOPHILIA MARKET WITH GENE EDITING

Prnewswire | August 28, 2020

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop ...

Read More
news image

Pharma Tech

MARK CUBAN COST PLUS DRUG COMPANY AND HEALTHDYNE ANNOUNCE PHARMACY PARTNERSHIP

PRNewswire | June 08, 2023

Ongoing changes in the healthcare industry have fueled innovators to reinvent the future, forge new paths, make smart decisions, and find aligned partners to disrupt the traditional pharmacy space. HealthDyne and Cost Plus Drugs have partnered to deliver pharmacy solutions for a new era in medication therapy distribution. HealthDyne, the national provider of digital pharmacy services, was selected by Cost Plus Drugs to expand its pharmacy operations. "Healthcare companies h...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us